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Objective: Brain structural changes in schizoaﬀective disorder, and how
far they resemble those seen in schizophrenia and bipolar disorder, have
only been studied to a limited extent.
Method: Forty-ﬁve patients meeting DSM-IV and RDC criteria for
schizoaﬀective disorder, groups of patients with 45 matched
schizophrenia and bipolar disorder, and 45 matched healthy controls
were examined using voxel-based morphometry (VBM).
Results: Analyses comparing each patient group with the healthy
control subjects found that the patients with schizoaﬀective disorder
and the patients with schizophrenia showed widespread and
overlapping areas of signiﬁcant volume reduction, but the patients with
bipolar disorder did not. A subsequent analysis compared the combined
group of patients with the controls followed by extraction of clusters. In
regions where the patients diﬀered signiﬁcantly from the controls, no
signiﬁcant diﬀerences in mean volume between patients with
schizoaﬀective disorder and patients with schizophrenia in any of ﬁve
regions of volume reduction were found, but mean volumes in the
patients with bipolar disorder were signiﬁcantly smaller in three of ﬁve.
Conclusion: The ﬁndings provide evidence that, in terms of structural
gray matter brain abnormality, schizoaﬀective disorder resembles
schizophrenia more than bipolar disorder.
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Signiﬁcant outcomes
• Patients with schizoaﬀective disorder showed widespread areas of gray matter reduction similar to
those observed in schizophrenia
• Gray matter reductions were more extensive in patients with both schizophrenia and schizoaﬀective
disorder than in patients with bipolar disorder, suggesting that schizoaﬀective disorder resembles
schizophrenia more than bipolar disorder
• Neuroimaging may provide a useful source of evidence in the ongoing debate about the nosological
position of schizoaﬀective disorder
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Limitations
• Gray matter diﬀerences were found in the comparisons between the patients and the controls; diﬀer-
ences among the patient groups themselves were not seen
• All patients were medicated, which might have inﬂuenced the results
• A sample of schizoaﬀective disorder, bipolar type, was studied, and the results should not be extrapo-
lated to schizoaﬀective disorder, unipolar type.
Introduction
Eighty years after the term was introduced by Kas-
anin (1), the nosology of schizoaﬀective disorder
remains elusive and controversial (2). At various
times, it has been argued that it should be consid-
ered an independent diagnostic entity (3), a variant
of schizophrenia (4), a variant of aﬀective disorder
(5), the midpoint on a continuum between the two
(6), or even a disorder which does not really exist
(7). Clinical studies have performed little to clarify
the status of the disorder, ﬁnding that it does not
clearly separate from schizophrenia or bipolar dis-
order, either cross-sectionally (8, 9), or in terms of
its course and outcome (for a review, see (10)).
Similarly, family history studies have found high
rates of aﬀective disorders in the ﬁrst-degree rela-
tives of patients with schizoaﬀective disorder, but
also elevated rates of schizophrenia (11–14).
Structural brain imaging could represent a fur-
ther source of evidence in this debate. Thus, while
schizophrenia is characterized by a reduction in
whole volume of around 2%, coupled with larger
reductions in regions such as the frontal lobe and
the hippocampus (15), bipolar disorder appears to
be associated with only at most minor whole brain
and regional volume changes (16, 17). Few studies
have examined schizoaﬀective disorder using con-
ventional CT or MRI measures (18–21), and these
have mostly been underpowered and have not
demonstrated clear diﬀerences from either schizo-
phrenia or bipolar disorder.
Studies using newer structural imaging tech-
niques like voxel-based morphometry (VBM)
might be more informative in this respect, given
that they map volume change across the whole
brain, without the necessity of preselecting regions
of interest. Schizophrenia and bipolar disorder
have been found to show diﬀerent patterns of gray
matter change using this technique: Ellison-Wright
and Bullmore (22) meta-analyzed 42 VBM studies
of schizophrenia and 14 of bipolar disorder and
found that the distribution of gray matter volume
reductions was wide in schizophrenia, aﬀecting the
frontal, temporal, cingulate and insular cortex, and
the thalamus. In contrast, reductions in bipolar
disorder were restricted to the anterior cingulate
cortex and bilateral insula. Bora et al. (23) had
similar ﬁndings in a subsequent meta-analysis,
although they noted that the diﬀerences became
less marked when a predominance of male patients
in schizophrenia studies but not in patients with
bipolar disorder was controlled for.
To date, there have been only two VBM studies
of schizoaﬀective disorder, both from the same
group. In the ﬁrst of these, Ivleva et al. (24) exam-
ined 19 patients with schizophrenia, 16 with schi-
zoaﬀective disorder, and 17 with bipolar psychotic
disorder, as well as 10 healthy controls. They
found decreased gray matter volume in the patients
with schizophrenia, and there were similar, albeit
less extensive, changes in the patients with schizo-
aﬀective disorder; however, the patients with bipo-
lar disorder did not diﬀer from the controls. In a
larger study which combined MRI data from four
diﬀerent centers, Ivleva et al. (25) found that 146
patients with schizophrenia and 90 patients with
schizoaﬀective disorder both showed gray matter
volume reductions in numerous and overlapping
areas compared to 200 healthy controls. In con-
trast, 115 patients with psychotic bipolar disorder
showed volume reductions that were limited to the
frontotemporal cortex. In both studies, it should
be noted, no diﬀerences were detected in pairwise
comparisons among the three patient groups.
Aims of the study
The aim of this study was to examine, by means of
voxel-based morphometry, patterns of brain struc-
tural abnormality in well-matched samples of
patients with schizoaﬀective disorder, schizophre-
nia, and bipolar disorder. Healthy controls were
also employed.
Material and methods
Subjects
Forty-ﬁve patients with schizoaﬀective disorder,
bipolar type, were recruited from the inpatient
units and outpatient departments of three psychi-
atric hospitals in the Barcelona area: Hospital
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Benito Menni in Sant Boi, Hospital Clınic of Bar-
celona, and Hospital General of Granollers. All
patients were diagnosed using DSM-IV criteria,
based on a detailed clinical interview and review of
case notes. In view of a number of weaknesses
identiﬁed with the DSM-IV diagnosis of schizoaf-
fective disorder (26), we also required the patients
to meet the more detailed and somewhat stricter
Research Diagnostic Criteria (RDC) (27). Diagno-
ses were made based on a detailed clinical inter-
view and review of case notes carried out by a
single member of the study team (BLA). The
schizoaﬀective sample included 15 patients who
were schizomanic at the time of evaluation, 15 who
were schizodepressed, and 15 who only showed
minor aﬀective and psychotic symptoms.
Groups of patients with schizophrenia (n = 45)
and bipolar disorder (n = 45), diagnosed according
to DSM-IV, were recruited from the same three
hospitals. Once again diagnoses were made based
on a detailed clinical interview and review of case
notes. The schizophrenic sample included 20
patients with acute psychotic symptoms and 25
patients stabilized at the time of evaluation and
MRI scanning session. All the patients with bipo-
lar disorder had bipolar I disorder, and 32 had a
history of psychotic symptoms (71%). The sample
included 15 patients who were manic, 15 who were
in a depressive phase, and 15 who were euthymic
at the time of evaluation. Normally, patients were
admitted to the hospitals in an acute state, in a
manic or depressed episode for patients with bipo-
lar disorder or schizodepressed or schizomanic
phase for schizoaﬀective disorder fulﬁlling corre-
sponding diagnostic criteria. Some patients were
also scanned while being in euthymia or clinical
remission, recruited from the corresponding outpa-
tient clinics.
All patients were right handed. Exclusion crite-
ria for all three groups were age younger than 18
or older than 65 years, history of neurological dis-
ease or brain trauma, and alcohol/substance abuse
in the 12 months prior to participation. Patients
were also required to have a current IQ in the nor-
mal range (>70).
Right-handed healthy subjects (n = 45) were
recruited via poster and web-based advertisement
in the hospital and local community, plus word-of-
mouth requests from staﬀ in the research unit.
They met the same exclusion criteria as the
patients, and they were interviewed and excluded if
they reported a history of mental illness and/or
treatment with psychotropic medication other than
non-regular use of benzodiazepines or similar
drugs for insomnia. They were also questioned
about family history of mental illness and excluded
if a ﬁrst-degree relative had experienced symptoms
consistent with major psychiatric disorder and/or
had received any form of in- or outpatient psychi-
atric care.
The three patient groups and the healthy con-
trols were selected to be matched with the schizoaf-
fective sample on demographic variables, and on
premorbid IQ, as estimated using the Word Accen-
tuation Test (Test de Acentuacion de Palabras,
TAP) (28, 29). This test is conceptually similar to
the UK National Adult Reading Test (30) and the
American Wide-Range Achievement Test (31) and
requires pronunciation of Spanish words whose
accents have been removed. Current IQ was mea-
sured using four subtests of the Wechsler Adult
Intelligence Scale III (WAIS-III) (vocabulary, sim-
ilarities, block design, and matrix reasoning).
The study was carried out in accordance with
the latest version of the Declaration of Helsinki
and was approved by the research ethics committee
(Comite Etico de Investigacion Clınica de las Her-
manas Hospitalarias, Barcelona). Written
informed consent was obtained for all subjects.
Structural imaging
All subjects underwent structural MRI scanning in
a single session, using the same 1.5 Tesla GE Signa
scanner (General Electric Medical Systems, Mil-
waukee, WI), located at the Sant Joan de Deu
Hospital in Barcelona, Spain.
Structural T1-weighted MRI data were acquired
using 180 contiguous axial slices with thickness of
1 mm. The images were collected in a 256 9 224
acquisition matrix and were zero-ﬁlled in the
k-space by the scanner to yield an image of
512 9 512 pixels with reconstruction diameter of
240 mm, resulting in an eﬀective in-plane voxel
size of 0.47 9 0.47 mm2. The echo (TE), repetition
(TR) and inversion (TI) times were equal to (TE/
TR/TI) = 3.93 ms/2000 ms/710 ms respectively.
The ﬂip angle was 15 degrees, and the total acquisi-
tion time was approximately 5 min. All images
were visually inspected to detect any artifact.
Structural data were analyzed with FSL-VBM,
an optimized voxel-based morphometry style
analysis (32) carried out with FSL tools (33), which
allows to detect potential diﬀerences in the local
gray matter volume between diﬀerent groups of
subjects. In a ﬁrst step, structural images were
brain-extracted using BET (34). Next, tissue-type
segmentation was carried out and the resulting
gray matter partial volume images were aligned to
the MNI152 standard space using the FSL tools
FLIRT and FNIRT. The resulting images were
averaged to create a study-speciﬁc template, to
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which the native gray matter images were nonlin-
early re-registered. These images were modulated
(to correct for local expansion or contraction) by
multiplying by the Jacobian of the warp ﬁeld, and
they were later smoothed with an isotropic Gauss-
ian kernel with a sigma of 4 mm (approximately
corresponding to FWHM of 9.4 mm). No images
were discarded due to artifacts or technical rea-
sons.
Statistical analyses
Demographic and clinical data. Diﬀerences in
demographic and clinical characteristics among
the groups were examined using chi-square tests
for categorical variables and one-way ANOVA tests
for continuous variables, with pairwise chi-square/
Tukey post hoc comparisons in case of statistical
signiﬁcance.
Inter-group VBM comparisons. Voxel-based mor-
phometry comparisons were carried out using a
voxel-wise general linear model (GLM) and per-
mutation-based nonparametric testing as imple-
mented in FSL randomize programme, using the
threshold-free cluster enhancement (TFCE)
method (35) and 10 000 permutations. In the ﬁrst
step, each patient group was individually com-
pared with the healthy control subjects. The three
patient groups were also compared with each
other. Anatomical locations of signiﬁcant clusters
were determined by reference to the MNI struc-
tural atlas integrated into FSLView (part of FSL),
the AAL atlas within MRICRON software (http://
www.mccauslandcenter.sc.edu/mricro/mricron/index.
html), and the XJVIEW toolbox for SPM (http://
www.alivelearn.net/xjview8/).
VBM of the combined patient group and controls with
subsequent analysis of the resulting significant clus-
ters. Given that schizophrenia, bipolar disorder
and presumptively schizoaﬀective disorder are all
characterized by gray matter volume reductions,
structural imaging diﬀerences between these
patient groups are likely to be more diﬃcult to
detect than those between a patient group and con-
trols (e.g., 36). Therefore, a further, region-
of-interest (ROI)-based analysis was conducted to
detect potential diﬀerences between patients
groups. For this, the healthy control group was
ﬁrst compared with the combined patient group.
This analysis allowed the identiﬁcation of rele-
vant aﬀected regions related to the illnesses.
Then, in a second step, the volume on these
detected regions was compared between the three
patient groups.
Threshold. In all the whole-brain analyses, a
threshold of P = 0.01, family-wise error (FWE)
corrected for multiple comparisons across space,
was used. We applied this relatively conservative
threshold to minimize false-positive ﬁndings aris-
ing from the fact that six diﬀerent inter-group
comparisons were carried out. For completeness,
we also report results applying a corrected thresh-
old of P = 0.05. For the ROI analysis, correction
for multiple comparisons was carried out using the
Bonferroni method.
Results
Demographic and clinical data
The ﬁndings for the three patient groups and
the controls are shown in Table 1. The groups
were preselected to be matched for age, sex, and
estimated premorbid IQ (TAP score); they were
also not signiﬁcantly diﬀerent in duration of ill-
ness. As expected, the patients with schizophre-
nia showed a lower current IQ than the healthy
controls. This also applied to the patients with
schizoaﬀective disorder and the patients with
bipolar disorder.
The number of patients receiving atypical anti-
psychotics was higher than the number of patients
receiving typical antipsychotics in all three groups
(patients with bipolar disorder: 68% vs. 24%;
patients with schizophrenia: 92% vs. 35%; patients
with schizoaﬀective disorder: 87% vs. 33%). There
were statistically signiﬁcant diﬀerences in the
chlorpromazine equivalent dosages of total and
atypical antipsychotic doses between patients with
bipolar disorder and schizophrenia (Table 1).
VBM comparison of each patient group with the healthy controls
At a corrected threshold of P < 0.01, both patients
with the schizophrenia and the schizoaﬀective dis-
order showed areas of volume reduction in rela-
tively widely distributed and broadly similar
cortical locations. In contrast, the patients with
bipolar disorder showed no areas of volume reduc-
tion compared to the healthy controls. There were
no areas of signiﬁcant gray matter volume increase
in any of the patient groups. The ﬁndings for the
patients with schizophrenia and schizoaﬀective dis-
order are shown in Fig. 1, and the locations of the
clusters are listed in Table 2.
Results for the above analyses at a corrected
threshold of P < 0.05 are reported in the Supple-
mentary Material. The ﬁndings in the patients with
schizophrenia and schizoaﬀective disorder
remained broadly similar, with both groups showing
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widespread and overlapping areas of volume
reduction. At this less conservative threshold, how-
ever, the patients with bipolar disorder also
showed a cluster of signiﬁcant gray matter volume
reduction located in the right middle temporal
gyrus and also covering parts of the right superior
temporal cortex [peak in MNI (54, 28, 8),
P < 0.02].
Table 1. Demographic characteristics of patients with schizophrenia (n = 45), schizoaffective disorder (n = 45), and bipolar disorder (n = 45); and healthy controls (n = 45)
BD SZ SAD HC P-value
Age (years) 42.9  9.2 43.2  9.1 43.3  9.0 43.3  9.9 n.s.
Sex (male/female) 26/19 26/19 26/19 26/19 n.s.
Estimated premorbid IQ (TAP) 101.5  8.5 100.1  9.9 100.5  9.8 101.0  10.1 n.s.
Current IQ (WAIS-III) 92.0  18.2 90.0  16.2 88.9  15.0 104.0  16.5 <0.001*
Duration of illness (years) 17.6  11.8 21.5  9.8 18.8  10.9 n.a. n.s.
Positive syndrome (PANSS) 9.7  5.3 13.3  5.5 13.3  5.7 n.a. 0.005†
Negative syndrome (PANSS) 10.4  6.1 17.8  6.3 11.9  6.4 n.a. <0.001‡
Disorganized syndrome (PANSS) 6.6  2.6 10.7  4.5 6.7  2.3 n.a. <0.001‡
YMRS score 8.5  10.9 n.a. 8.8  9.8 n.a. n.s.
MADRS score 13.8  14.4 n.a. 11.3  12.7 n.a. n.s.
Antipsychotic dose (CPZ equivalents) 428  565 852  709 694  602 n.a. 0.015§
Typical 49  152 121  335 154  432 n.a. n.s.
Atypical 379  515 731  554 541  433 n.a. 0.012§
Number receiving lithium 15 2 8 n.a. 0.001§
Number receiving anticonvulsants 13 2 21 n.a. <0.001‡
Values are mean  standard deviation.
HC, healthy controls; BD, bipolar disorder; SZ, schizophrenia; SAD, schizoaffective disorder; TAP, Word Accentuation Test (Test de Accentuacion de Palabras); PANSS, Positive
Syndrome Scale; WAIS-III, Wechsler Adult Intelligence Scale; CPZ equival., Chlorpromazine equivalents.
*Statistically significant differences between HC and all groups of patients.
†Statistically significant differences between SC and BIP, and between SAD and BIP.
‡Statistically significant differences between SAD and SC, and between BIP and SC.
§Statistically significant differences between BIP and SC.
(a)
(b)
Fig 1. Brain regions showing signiﬁcant gray matter volume reduction in patients with schizophrenia and schizoaﬀective disorder in
relation to the healthy controls group (n = 45) at P < 0.01, corrected for multiple comparison across space via a threshold-free clus-
ter enhancement procedure. Top panel (a) Volume reductions in the patients with schizophrenia (n = 45). Bottom panel (b) Volume
reductions in the patients with schizoaﬀective disorder (n = 45). The patients with bipolar disorder showed no areas of volume reduc-
tion. The right side of the image is the right side of the brain.
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VBM comparisons among the patient groups
At P < 0.01 corrected, there were no areas of sig-
niﬁcant gray matter volume diﬀerence in any of
the comparisons. At the less conservative corrected
threshold P < 0.05, the patients with bipolar disor-
der showed areas of increased volume in the cere-
bellum as compared with the patients with
schizophrenia (two main peaks: [peak 1 in MNI
(22, 60, 48), P < 0.02; peak 2 in MNI (20,
64, 46), P < 0.02]) and the patients with schizo-
aﬀective disorder ([peak in MNI (32, 60, 44),
P < 0.03]).
VBM comparisons of the combined patient group with the healthy
controls
At a corrected threshold of P < 0.01, this analy-
sis revealed seven clusters of signiﬁcant diﬀer-
ence between the controls and the combined
patient group, all representing volume reductions
in the patients. One was centered in the medial
frontal cortex bilaterally, including parts of the
gyrus rectus, the anterior cingulate cortex, and
portions of the medial and superior frontal
gyrus (three main peaks: [peak 1 in MNI (22,
30, 24), P < 0.002; peak 2 in MNI (4, 14, 48),
P < 0.006; peak 3 in MNI (18, 38, 38),
P < 0.002]). There were also two bilateral clus-
ters located in the superior frontal gyrus
(L > R), with the cluster on the left also reach-
ing the supplementary motor area and middle
part of the cingulate gyrus (two main peaks:
[peak 1 in MNI (18, 38, 38), P < 0.002; peak
2 in MNI (20, 22, 48), P < 0.006]). Additionally,
there was a large right-sided cluster including
parts of the insula and rolandic operculum, the
inferior, middle and superior temporal cortex,
the hippocampus, and reaching the postcentral,
parietal, supramarginal, paracentral lobule, and
the supplementary motor area (three main
peaks: [peak 1 in MNI (62, 2, 4), P < 0.0006;
peak 2 in MNI (30, 74, 52), P < 0.002; peak 3
in MNI (2, 10, 36), P < 0.009]). Another large
cluster was located in the left hemisphere,
including parts of the insula and rolandic oper-
culum, the inferior, middle, and superior tempo-
ral cortex, reaching the postcentral, parietal,
Table 2. Results from the voxel-based morphometry analyses comparing the patients with schizophrenia (n = 45) and schizoaffective disorder (n = 45) with healthy controls
(n = 45)
Group comparison MNI Coordinates (x,y,z) P-value Number of voxels Breakdown (structures)
SZ vs. HC
Patients>HC
(none)
Patients<HC
Right anterior cingulate (1, 12, 49) <0.005 3577 Bilateral anterior cingulate and gyrus rectus
Left supplementary motor area (10, 20, 56) <0.003 1651 Left supplementary motor area and left superior frontal gyrus
Left paracentral lobule (7, 25, 76) <0.01 97 Left paracentral lobule
Left insula (38, 17, 6) <0.0005 5347 Left insula, rolandic operculum, hippocampus and superior,
middle and inferior left temporal cortex
Right superior temporal cortex (46, 29, 7) <0.0002 6189 Superior, middle and inferior right temporal cortex, right
Insula, rolandic operculum, and hippocampus
Right precuneus (11, 62, 65) <0.005 256 Right precuneus
Left inferior parietal (48, 50, 52) <0.003 1508 Left inferior and superior parietal cortex and left postcentral
Right cerebellum (20, 70, 38) <0.001 811 Right cerebellum
Left cerebellum (22, 64, 48) <0.001 1184 Left cerebellum
SAD vs. HC
Patients>HC
(none)
Patients<HC
Right anterior cingulate (4, 12, 50) <0.001 6578 Bilateral anterior cingulated cortex and gyrus rectus, bilateral
superior frontal gyrus, and frontal medial orbital
Left paracentral lobule (4, 14, 72) <0.001 6480 Bilateral paracentral lobule, bilateral postcentral, parietal,
supramarginal, supplementary motor area, and medium cingulate
Left insula (34, 6, 12) <0.001 6659 Left insula, rolandic operculum, and the superior, middle, and
inferior left temporal cortex
Right superior temporal cortex (56, 10, 6) <0.0006 7238 Superior, middle, and inferior right temporal cortex, right insula,
rolandic operculum, and hippocampus.
Right cuneus (20, 64, 32) <0.003 1816 Right cuneus, precuneus, calcarine, and superior occipital pole
Left occipital middle (27, 93, 10) <0.003 3163 Inferior, middle, and superior left occipital pole, left lingual,
calcarine, and precuneus
Right cerebellum (12, 56, 26) <0.001 476 Right cerebellum
Left cerebellum (22, 56, 34) <0.0005 616 Left cerebellum
HC, healthy controls; SZ, schizophrenia; SAD, schizoaffective disorder; BD, bipolar disorder.
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supramarginal, precentral lobule, and extending
to the supplementary motor area (two main
peaks: [peak 1 in MNI (60, 2, 2),
P < 0.002; peak 2 in MNI (58, 18, 44),
P < 0.002]). Finally, there were two bilateral
clusters situated in the cerebellum ([peak 1 in
MNI (10, 62, 28), P < 0.0006; peak 2 in
MNI (12, 62, 28), P < 0.002]).
The above seven clusters were ﬁrst reduced to
ﬁve, by combining the roughly symmetrical bilat-
eral clusters in the superior frontal cortex and in
the cerebellum. The mean gray matter volumes for
each group in these ﬁve regions are shown in
Fig. 2. At P < 0.05 correcting for multiple com-
parisons, there were no signiﬁcant diﬀerences
between the patients with schizoaﬀective disorder
and schizophrenia in any of the regions. However,
both patients with the schizophrenia and the
schizoaﬀective disorder showed signiﬁcantly
greater volume reductions than the bipolar group
in bilateral regions located in the temporo-insular-
parietal cortex, as well as in the cerebellum.
Discussion
Main findings
The patients with schizophrenia and schizoaﬀec-
tive disorder in this study both showed a pattern of
widespread gray matter volume reduction com-
pared to healthy controls, whereas the patients
with bipolar disorder did not. A subsequent analy-
sis comparing the combined group of patients with
the controls followed by extraction of clusters
found that, in regions where the patients diﬀered
signiﬁcantly from the controls, the changes were
uniformly in the direction of greater volume loss in
the patients with schizophrenia and schizoaﬀective
disorder than in the patients with bipolar disorder,
although the diﬀerences were not always signiﬁ-
cant.
As noted in the introduction, only two other
studies to date have examined schizoaﬀective dis-
order using VBM. In the ﬁrst of these (24), which
was carried out on small numbers of subjects (<20
in each group), the patients with schizophrenia and
schizoaﬀective disorder, but not the patients with
bipolar disorder showed volume reductions com-
pared to healthy controls; the changes also
appeared to be considerably more extensive in the
patients with schizophrenia than the patients with
schizoaﬀective disorder. The second, much larger,
study (25) had ﬁndings similar to ours: 146 patients
with schizophrenia and 90 patients with schizoaf-
fective disorder showed gray matter volume reduc-
tions compared to 200 healthy controls in
numerous and overlapping areas, whereas changes
in 115 patients with psychotic bipolar disorder
were restricted to a single cluster in the frontotem-
poral cortex.
In contrast, neither our study nor that of Ivleva
et al. (25) found signiﬁcant diﬀerences when the
three patient groups were compared with each
other. At 45 per group, numbers in our study were
reasonably large and suﬃcient to show diﬀerences
from healthy controls. In the study of Ivleva et al.
(25), the numbers were much larger, although the
fact that they obtained MRI data from four diﬀer-
ent centers would have inevitably introduced noise
into the analysis. A plausible explanation for the
negative ﬁndings here is that diﬀerences between
groups of patients characterized by greater or les-
ser degrees of volume reduction will always be
smaller than the diﬀerences from healthy controls
(25). In this respect, it is interesting to note that,
while Ellison-Wright and Bullmore (22) found evi-
dence for more extensive volume reductions in
schizophrenia than bipolar disorder in their meta-
analysis of VBM studies, a later meta-analysis by
Bora et al. (23) found that the diﬀerences became
considerably less marked when the predominance
of male patients in the schizophrenia studies, they
included was corrected for. De Peri et al. (37) also
found largely similar whole-brain volume reduc-
tions in ﬁrst-episode patients with schizophrenia
and bipolar disorder in a meta-analysis of conven-
tional MRI studies, although gray matter reduc-
tions were somewhat more pronounced in the
former and white matter reductions in the latter.
Findings in the patients with schizophrenia and bipolar disorder
The volume reductions we found in the schizo-
phrenic group aﬀected the medial frontal cortex,
the insula, the pre- and postcentral gyri, the hippo-
campus, parts of the temporal lobe cortex, the pre-
cuneus, the inferior parietal cortex, and the
cerebellum. These are in reasonable agreement
with the results of other studies of schizophrenia;
in particular, all of the changes apart from those in
the precuneus and inferior parietal cortex were
identiﬁed in a systematic review of meta-analyses
of VBM studies (38).
On the other hand, the bipolar group showed no
areas of brain volume reduction compared to the
controls. This ﬁnding goes against those of other
VBM studies of patients with bipolar disorder,
meta-analyses of which have found the anterior
cingulate cortex, the insula, and the inferior frontal
cortex to show volume reductions, among other
areas (22, 39, 40). The likeliest explanation of our
failure to detect diﬀerences is the use of a restrictive
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threshold of at a P = 0.01 corrected. In support of
this, when we used a more liberal threshold of
P = 0.05 corrected a cluster of volume reduction
emerged in the right temporal lobe cortex.
Similarities and differences between the schizoaffective and
schizophrenic brain changes
Gray matter volume reductions in the patients with
schizoaﬀective disorder followed a substantially
similar pattern to those seen in the patients with
schizophrenia: in both groups, changes were seen
in the medial frontal cortex, a large region incorpo-
rating the insula, the rolandic operculum, parts of
the temporal lobe, and the hippocampus. There
were also volume reductions in the pre- and post-
central cortex, the supplementary motor area, and
the cerebellum in both patient groups. The over-
lap, however, was not complete: areas aﬀected in
the patients with schizophrenia but not the patients
with schizoaﬀective disorder included the left infe-
rior parietal cortex, the supplementary motor area,
and the right precuneus; in contrast, the right pre-
cuneus and the left occipital cortex were aﬀected in
the patients with schizoaﬀective disorder but not
the patients with schizophrenia.
These diﬀerences might simply have reﬂected
sampling error—it seems possible that if two groups
of patients with schizophrenia of the size we used
were compared to the same group of healthy con-
trols, diﬀerences might also have emerged. Another
possibility is that the diﬀerences found reﬂected the
symptomatic diﬀerences of the two disorders, for
example, the lack of major mood change in schizo-
phrenia, or a lesser degree of negative symptoms in
schizoaﬀective disorder. In this respect, it is interest-
ing to note that neither the right precuneus and the
left occipital cortex that were aﬀected in the patients
with schizoaﬀective disorder but not the patients
with schizophrenia appeared in Shepherd et al.’s
(38) review of meta-analyses of VBM studies of
schizophrenia. On the other hand, the view that
negative symptoms (or other schizophrenic symp-
toms) have brain structural correlates is far from
clearly established (41–47).
Nosological implications
What consequences do our ﬁndings have for the
nosological status of schizoaﬀective disorder? They
are clearly incompatible with the argument that
schizoaﬀective disorder is a variant of bipolar dis-
order (5, 48, 49). Nor are they easy to reconcile
with the longstanding—and currently highly topi-
cal—proposal that schizoaﬀective disorder repre-
sents the midpoint along a continuum of
psychosis, as conceptualized either genetically
(6, 13), clinically (8, 50, 51), or both (52). This
would predict less volume change in schizoaﬀective
disorder than in schizophrenia, something that
none of the analyses carried out in this study
supported.
Our and Ivleva et al.’s (25) ﬁndings appear most
compatible with schizoaﬀective being a variant of
schizophrenia. This is a proposal that is currently
unfashionable to the extent that it is diﬃcult to
ﬁnd publications that have advocated it since Leh-
man et al. (e.g., 4), over thirty years ago (4).
Another less controversial possibility might be that
schizoaﬀective disorder is an intermediate form of
illness, but one that is, for unknown reasons,
skewed toward schizophrenia.
Strengths of the study
In our study, we used both DSM-IV and RDC
criteria for schizoaﬀective disorder, with the lat-
ter being widely regarded as providing the partic-
ularly rigorous and detailed diagnostic guidelines.
Both criteria require the presence of delusions or
hallucinations for at least 2 weeks in the absence
of prominent mood symptoms, and so, in prac-
tice mean that there must be some separation
between psychotic and aﬀective symptoms in a
particular episode. This has the advantage of
avoiding confusion with psychotic forms of bipo-
lar disorder, something to which ICD-10 criteria
are vulnerable, because they do not require the
absence of aﬀective in the presence of psychotic
symptoms. Perhaps in line with this J€ager et al.
(2) found that patients meeting DSM-IV criteria
for schizoaﬀective disorder had a more unfavor-
able outcome than patients diagnosed following
ICD-10 criteria.
The VBM analyses were performed using stan-
dard validated procedures and TFCE correction
for multiple comparisons, a relatively new tech-
nique that may be more sensitive to detect the
underlying morphological diﬀerences than other
available approaches (53).
Fig 2. Comparisons of gray matter volume reduction averaged over the clusters in schizoaﬀective disorder (n = 45), schizophrenia
(n = 45), and bipolar disorder (n = 45) in the following regions: (a) ventromedial prefrontal cortex, (b) bilateral frontal superior cor-
tex, (c) right temporo-insular-parietal areas, (d) left temporo-insular-parietal areas, and (e) bilateral cerebellum. Boxplots are based
on mean percentage of volume reduction compared to the healthy controls group. ** individual t-tests signiﬁcant at a corrected
P < 0.01, * signiﬁcant at a corrected P < 0.05. The right side of the image is the right side of the brain.
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Limitations
We examined groups of patients with schizoaﬀec-
tive disorder and bipolar disorder with mixed, that
is, manic, depressed and euthymic, presentations,
and the majority of the bipolar sample presented
with a history of psychotic symptoms but not all of
them. Both might have potentially inﬂuences
results. We also did not match the patients with
schizoaﬀective disorder and the patients with bipo-
lar disorder for numbers of episodes of illness,
principally because this presented diﬃculties in the
patients with schizoaﬀective disorder. Beyond this,
our samples were made up exclusively of right-
handed patients, which could represent a sampling
bias, as left-handedness has been found to be over-
represented in schizophrenia. We excluded current
drug or alcohol abuse, but data on substance abuse
in the past were not systematically collected and
could have diﬀered between groups. Finally and in
common with other neuroimaging studies of psy-
chosis, the patients were medicated, which both in
the case of antipsychotics (54, 55) and lithium (56)
has the potential to inﬂuence brain volume (23).
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